Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
German Breast Group |
---|---|
Information provided by: | German Breast Group |
ClinicalTrials.gov Identifier: | NCT00661739 |
The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in a weekly schedule. The two agents have different toxicity profiles and are well tolerated when given in a weekly fashion. The combination might be of special interest for elderly patients with hormone insensitive breast cancer
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: Bendamustine |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer |
Enrollment: | 18 |
Study Start Date: | July 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GBG Forschungs GmbH ( Silke Weykam ) |
Study ID Numbers: | GBG 38 |
Study First Received: | April 15, 2008 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00661739 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
palliative Breast cancer metastatic Bendamustine phase I |
Skin Diseases Paclitaxel Breast Neoplasms Breast Diseases Bendamustine |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses |
Mitosis Modulators Tubulin Modulators Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |